Desmoplakin I/ II immunohistochemical staining may be a helpful tool in differentiating cutaneous graft versus host disease from the erythema multiforme, Stevens–Johnson syndrome, and toxic epidermal necrolysis spectrum disorders
Journal of Cutaneous Pathology · 2024
DOI: 10.1111/cup.14513 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cutaneous Pathology, 2024. Verfasst von Trent Irwin und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA. Hauptthemen laut MEDLINE: Stevens-Johnson Syndrome, Erythema Multiforme, Graft vs Host Disease. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: University of Washington.
Abstract (Originalsprache)
Cutaneous graft versus host disease (cGVHD) has substantial clinical and histopathologic overlap with erythema multiforme (EM), Stevens–Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN). This overlap can make it difficult to distinguish these disorders in patients who have received hematopoietic transplants. We sought to evaluate the utility of Dp I/II immunohistochemical stain in differentiating EM/SJS/TEN and cGVHD in a large cohort. Skin biopsy specimens from patients with cGVHD ( n = 58) and EM/SJS/TEN ( n = 60) were evaluated for Dp I/II expression by immunohistochemistry. We found a statistically significant difference in Dp I/II staining between cGVHD (all grades) and EM/SJS/TEN (mean scores 1.62 and 2.14, respectively; p < 0.005), as well as between Grades 2 + 3 cGVHD and EM/SJS/TEN (mean scores 2.26 and 1.62, respectively; p < 0.005), while we did not find a significant difference between Grade 4 cGVHD and EM/SJS/TEN (mean scores 1.69 and 1.62, respectively; p = 0.71). Dp I/II immunostain may be useful for differentiating EM/SJS/TEN from Grade 2 and Grade 3 cGVHD, especially in clinically ambiguous cases without extracutaneous GVHD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
- Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
- Division of Dermatology, Department of Medicine, University of Washington, Seattle, Washington, USA.
ORCID-Profile: Trent Irwin
Förderung
- University of Washington
Zitieren
APA
Irwin, T., Yeung, C. C. S., & Shinohara, M. M. (2024). Desmoplakin I/ II immunohistochemical staining may be a helpful tool in differentiating cutaneous graft versus host disease from the erythema multiforme, Stevens–Johnson syndrome, and toxic epidermal necrolysis spectrum disorders. Journal of Cutaneous Pathology. https://doi.org/10.1111/cup.14513
Vancouver
Irwin T, Yeung CCS, Shinohara MM. Desmoplakin I/ II immunohistochemical staining may be a helpful tool in differentiating cutaneous graft versus host disease from the erythema multiforme, Stevens–Johnson syndrome, and toxic epidermal necrolysis spectrum disorders. Journal of Cutaneous Pathology. 2024. doi:10.1111/cup.14513
BibTeX
@article{Irwin2024,
author = {Irwin, Trent and Yeung, Cecilia C S and Shinohara, Michi M},
title = {Desmoplakin I/ II immunohistochemical staining may be a helpful tool in differentiating cutaneous graft versus host disease from the erythema multiforme, Stevens–Johnson syndrome, and toxic epidermal necrolysis spectrum disorders},
journal = {Journal of Cutaneous Pathology},
year = {2024},
doi = {10.1111/cup.14513}
}
EUVIMED